Skip to main content
. Author manuscript; available in PMC: 2008 Feb 15.
Published in final edited form as: Neuron. 2007 Feb 15;53(4):503–517. doi: 10.1016/j.neuron.2007.01.009

Figure 2. Olig2 is required for glioma formation from neural stem cells.

Figure 2

(A) Strategy for murine glioma model utilizing genetically defined neural stem cells as the cell of origin. 2 x 105 Ink4a/Arf−/−EGFRvIII neurosphere cells of the indicated genotypes were transplanted orthotopically into the striatum of SCID mice and animals monitored for symptoms of glioma formation. (B) Kaplan-Meier survival analysis. SCID mice injected with Olig1/2 +/− or Olig1−/− Ink4a/Arf−/−EGFRvIII neurospheres die from tumors with short latency (median survival=69 days and 81 days, respectively) relative to mice injected with Olig1/2-null Ink4a/Arf−/−EGFRvIII neurospheres (96% survival at 273 days). Censored animals in the Olig1/2 −/− group (up ticks) indicate non-cancer deaths. p<0.01 for Olig1/2−/− versus Olig1−/− or Olig1/2+/−. (C) Kaplan-Meier survival analysis showing restoration of tumor phenotype in Olig deficient mice by Olig2 encoding retrovirus (orange) (median TFS = 132 days), but not control GFP virus (purple) (100% survival at 136 days), p<0.01.